公开(公告)号：US20170304273A1

公开(公告)日：2017-10-26

申请号：US15513277

申请日：2015-09-28

Applicant: KOWA COMPANY, LTD.

Inventor： Yuta Inokuchi ,  Haruki Shibata ,  Toshiaki Takizawa

IPC: A61K31/423 ,  A61K31/4152 ,  A61K45/06 ,  A61K45/00

CPC classification number: A61K31/423 ,  A61K31/4152 ,  A61K31/421 ,  A61K31/505 ,  A61K45/00 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans.This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl} acetic acid, a salt thereof, or a solvate of either.

公开(公告)号：US20170290841A1

公开(公告)日：2017-10-12

申请号：US15514259

申请日：2015-09-25

Applicant: KOWA COMPANY, LTD.

Inventor： Shin SUGIMOTO

IPC: A61K31/551 ,  A61K33/42 ,  A61K9/00 ,  A61K31/435

CPC classification number: A61K31/551 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/435 ,  A61K33/42 ,  A61K47/18

Abstract: An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition comprising a compound represented by Formula (1), wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a quaternary ammonium surfactant.

公开(公告)号：US20170246115A1

公开(公告)日：2017-08-31

申请号：US15290387

申请日：2016-10-11

Applicant: KOWA COMPANY, LTD.

Inventor： Chisa NISHIDA

IPC: A61K9/20 ,  A61K31/47 ,  A61K9/00

CPC classification number: A61K9/2054 ,  A61K9/0056 ,  A61K9/2027 ,  A61K31/47

Abstract: The present invention provides a pharmaceutical product which includes a solid preparation comprising pitavastatin or a salt thereof, in which production of a lactone form thereof is suppressed.The pharmaceutical product is characterized by including a solid preparation comprising the following ingredients (A) and (B): (A) pitavastatin or a salt thereof; and (B) at least one member selected from the group consisting of carmellose and a salt thereof, crospovidone, and microcrystalline cellulose, and the solid preparation having a water content of 2.9 mass % or less, wherein the solid preparation is stored in a tight package.

公开(公告)号：US09622653B2

公开(公告)日：2017-04-18

申请号：US14420511

申请日：2013-07-26

Applicant: Kowa Company, Ltd.

Inventor： Takuya Hara

IPC: A61B3/14 ,  A61B3/00 ,  A61B3/024 ,  A61B3/12

CPC classification number: A61B3/0025 ,  A61B3/0058 ,  A61B3/024 ,  A61B3/1225 ,  A61B3/14

Abstract: A perimeter 2 for measuring a visual field by conducting perimetry operations regarding measurement points RG of the subject eye 22a has means 17 for storing perimetry result, means 10, 24 for composing the perimetry result as a map image corresponding to a fundus and indicating it on the display 20, means 13 for obtaining and indicating a structure examination image PC1 of the subject eye 22a, means 16 for superimposing the map image MAP2 on the indicated structure examination image PC1 and indicating the superimposed as a composite image PC2, and means 15 for setting a concerned area NA on the composite image PC2, and means 21 for computing an evaluation value of the perimetry based upon the perimetry result.

公开(公告)号：US20170100409A1

公开(公告)日：2017-04-13

申请号：US15387113

申请日：2016-12-21

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION ,  KOWA COMPANY, LTD.

Inventor： Tatsuro Ishibashi ,  Shintaro Nakao ,  Ryoichi Arita ,  Ken Mizuno ,  Akifumi Tsuchiura

IPC: A61K31/551 ,  A61K9/00

CPC classification number: A61K31/551 ,  A61K9/0046 ,  A61K9/0048 ,  A61K31/496 ,  A61K47/10 ,  C07D401/12

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

公开(公告)号：US09596985B2

公开(公告)日：2017-03-21

申请号：US14395641

申请日：2013-04-17

Applicant: SHINSHU UNIVERSITY ,  KOWA COMPANY, LTD. ,  Kazuo Ichikawa

Inventor： Kazuo Ichikawa ,  Kiyoshi Tanaka ,  Tanaka Yoshiki

IPC: A61B3/02 ,  A61B3/06 ,  A61B3/032 ,  A61B3/00

CPC classification number: A61B3/066 ,  A61B3/0041 ,  A61B3/032

Abstract: [Problem] To be able to accurately measure color vision and color-viewing field for different colors.[Solution] The color-viewing function measuring means (1) pertaining to the present invention displays a plurality of chromatically colored targets (A11, . . . ) (for example, Landolt rings) in an achromatic background (B), the brightness of the targets (A11, . . . ) being set so as to be substantially equal to the brightness of the background (B). When vision or the viewing field is measured with this color-viewing function measuring means (1), vision and viewing field can be accurately measured for different colors.

公开(公告)号：US20170055824A1

公开(公告)日：2017-03-02

申请号：US15118651

申请日：2015-02-09

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi SHIMADA ,  Takuya HARA

IPC: A61B3/024 ,  A61B3/12 ,  A61B3/00

CPC classification number: A61B3/024 ,  A61B3/0008 ,  A61B3/0025 ,  A61B3/0033 ,  A61B3/0041 ,  A61B3/0058 ,  A61B3/0091 ,  A61B3/12

Abstract: In a perimetry to be conducted, designating an inspection region through a region designator, stimuli are presented to regions separated in an up/down direction, an oblique direction and a right/left direction from the inspection region (“the spaced region”) in addition to the designated inspection region. At the result, examinees are not able to predict to which of both regions, the inspection region and the spaced region the stimuli are presented, thereby obtaining correct inspection results that do not receive a prediction of the examinees.

Abstract translation: 在要进行的视野测量中，通过区域指示器指定检查区域，将刺激呈现在从检查区域（“间隔区域”）沿上/下方向，倾斜方向和左右方向分离的区域 除指定检验区外。 结果是，考生无法预测出两个区域中的哪个区域，检查区域和间隔区域的刺激情况，从而获得没有得到对受试者的预测的正确检查结果。

公开(公告)号：US09572798B2

公开(公告)日：2017-02-21

申请号：US14429449

申请日：2013-09-27

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397 ,  A61K45/06

CPC classification number: A61K31/423 ,  A61K31/397 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

Abstract translation: 本发明涉及提供用于预防和/或治疗诸如动脉粥样硬化，高胆固醇血症，包括人在内的哺乳动物中的低HDL血液病的血脂异常状况的药物组合组合物和药物组合的问题。 一种用于预防和/或治疗血脂异常等的药物组合物，其包含（a）由通式（1）表示的化合物（式中各符号与说明书中所定义的相同）或其盐 或其溶剂合物和（b）胆固醇吸收抑制剂。

公开(公告)号：US20170009955A1

公开(公告)日：2017-01-12

申请号：US15114331

申请日：2015-01-29

Applicant: KOWA COMPANY, LTD.

Inventor： Suguru Mukumoto

IPC: F21V3/02 ,  F21V17/16 ,  F21V7/00 ,  F21V23/04 ,  F21S8/04 ,  F21V13/08 ,  F21V19/00 ,  F21K9/272 ,  F21V9/08

CPC classification number: F21V3/02 ,  F21K9/272 ,  F21S4/28 ,  F21S8/04 ,  F21V3/06 ,  F21V7/0008 ,  F21V9/08 ,  F21V13/02 ,  F21V13/08 ,  F21V17/166 ,  F21V19/003 ,  F21V23/04 ,  F21Y2105/10 ,  F21Y2115/10

Abstract: LEDs (21) that emit illumination light and a cover unit (30) that houses the LEDs are provided. The cover unit is composed of a front cover part (31) that transmits, diffuses and reflects the illumination light from the LEDs and a rear cover part (32) that reflects the illumination light reflected at the front cover part again toward the front cover part. The front cover part and the rear cover part are integrally molded without a gap and the loss of light fluxes is therefore eliminated. Moreover, the uniformity of luminance distribution of the light-emitting surface is improved to solve the problem in that the side surfaces of the lighting device and the attaching surface (ceiling surface) are dark.

Abstract translation: 提供发射照明光的LED（21）和容纳LED的盖单元（30）。 盖单元由将LED的照明光透射，扩散反射的前盖部（31）和将前盖反射的照明光再次朝向前盖部反射的后盖部（32）构成， 。 前盖部分和后盖部分一体地模制而没有间隙，因此消除了光通量的损失。 此外，提高了发光面的亮度分布的均匀性，以解决照明装置的侧面和安装面（天花板面）较暗的问题。

公开(公告)号：US09526279B2

公开(公告)日：2016-12-27

申请号：US14678536

申请日：2015-04-03

Applicant: Kowa Company, Ltd.

Inventor： Kazuhiko Matsuo ,  Hidefumi Koga

IPC: A61F13/00 ,  A41D13/06 ,  A61F13/14 ,  A61F13/08 ,  A61F2/68 ,  A61F5/01 ,  A61F2/76

CPC classification number: A41D13/065 ,  A61F2/68 ,  A61F5/0109 ,  A61F5/0123 ,  A61F13/00 ,  A61F13/08 ,  A61F13/14 ,  A61F2002/7645 ,  A61F2210/0057

Abstract: A knee joint supporter which can improve the stability of the knee joint, reduce the wearer's fatigue and reduce the load on the patellar tendon includes a first anchor section formed by wrapping one end of a tubular knitted fabric around the wearer's thigh to tighten it with the fabric, a second anchor section formed by wrapping the other end of the fabric around the wearer's lower thigh to tighten it with the fabric, and a substantially U-shaped knitted supporting section joined to the first anchor section, covering the wearer's patella region and thus supporting the wearer's patella. In the circumferential direction of the fabric, the stretch resistance of the two anchor parts are larger than the stretch resistance of a base fabric section. In the length width direction of the fabric, the stretch resistance of the supporting section is larger than the stretch resistance of the base fabric section.